Zhejiang Medicine Co., Ltd.SSE: 600216

(600216)"Zhejiang Medicine Co., Ltd."Report for Q3 2026

· Issued by Zhejiang Medicine Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 600216 · · 12 pages · Chinese

Summary by 6ix AI

The report indicates significant declines in key financial metrics, including total revenue and net profit attributable to shareholders compared to the previous year. The company has confirmed that the financial statements have not been audited, and it emphasizes the accuracy and completeness of the reported information. The report also highlights the challenges faced due to declining market prices for its main products, which have adversely affected profitability.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Zhejiang Medicine Co., Ltd. on 6ix

Earlier from Zhejiang Medicine

All Zhejiang Medicine news releases